Research on Radiotracers and Novel Radiopharmaceuticals for Cancer Therapy and Diagnosis

Dear Colleagues,

It is commonly accepted that cancer is amongst the most prominent health issues arising from the increasing life expectancy worldwide. Great progress has been made over the years concerning both the diagnosis and treatment of cancer. In the last decade, nuclear medicine has made an undeniable contribution to clinical oncology, as new radiopharmaceuticals aimed at diagnosis or therapy (theranostics) have been developed. First with the radiolabelled somatostatin analogues approved by FDA/EMA and then with the implementation of PSMA inhibitors, a new era of clinically useful radiopharmaceuticals in personalized medicine has been paved. The introduction of novel molecular targets, both on cancer cells and in the malignancy microenvironment, is providing exciting new opportunities for radiopharmaceutical development.

In the hope of reviewing these efforts, we are pleased to invite you to share your results in this Special Issue titled “Research on Radiotracers and Novel Radiopharmaceuticals for Cancer Therapy and Diagnosis”. Original articles and reviews on radiopharmaceutical development, novel approaches to improving their performance, new cancer models for preclinical evaluation and clinical translation studies are most welcome.

Prof. Dr. Wei Lu
Dr. Panagiotis Kanellopoulos
Dr. Antonio Shegani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.